Slides From Hot Topics in NASH: Screening for NASH in Patients With Diabetes

Explore the latest on NASH screening and the interplay between NAFLD, metabolic syndrome, CV risk, and diabetes risk.
Kenneth Cusi, MD, FACP, FACE
Brent A. Neuschwander-Tetri, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.68 MB
Released: November 22, 2019

Acknowledgements

Provided by the American Gastroenterology Association.

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Allergan
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Unlocked slides from Giada Sebastiani, MD and CCO: Role of diet, exercise, and current treatments for NASH

person default Giada Sebastiani, MD Released: June 2, 2021

Expert advice on current NAFLD/NASH treatments: Mediterranean diet, vitamin E, pioglitazone, GLP-RAs, eg semaglutide. From Clinical Care Options (CCO)

person default Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: June 1, 2022

Unlocked slides from Wing-Kin Syn, MBChB, PhD, FACP, FRCP and CCO: How to use biomarkers and imaging to evaluate NAFLD and NASH—ruling in or out hepatic fibrosis

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Released: April 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue